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ABSTRACT 
 
A New Method in Subjective Tinnitus Management: 
The Use of a Nutraceutical Formulation to Improve Patient Outcomes 
 
 
by 
 
 
Jade H. Faulkner 
 
 
Advisor:  Dorothy Neave-DiToro, Au.D., CCC-A, FAAA 
 
 
Objective: This project aims to implement an evidence-based clinical practice guideline at the 
International Hearing Centre (IHC) in Lagos, Nigeria for future research and data collection of 
their subjective tinnitus management using a nutraceutical formulation called ‘NHANCED 
Hearing (NH).  After learning the IHC had incomplete charting in regard to tinnitus 
questionnaires pre- and post-administration of the NH formula, this capstone project sought to 
apply evidence-based guidelines for proper diagnostic evaluations and charting to assist in future 
research of the NH formula. 
Methodology:  A review and synthesis of current clinical practice guidelines in the United 
States, Germany, the Netherlands, Sweden, Denmark, and Japan allowed this research to present 
a complete diagnostic evaluation template and suggested timelines for administering subjective 
measures of tinnitus disturbance.  Future research with IHC will benefit from complete charting 
for a retrospective chart review including tinnitus-specific case history, audiologic pure tone 
thresholds, tympanometry and acoustic reflex thresholds, distortion product otoacoustic 
emissions, and completed Tinnitus Handicap Inventory (THI) administered at 3-month intervals. 
Results:  Future research will be analyzed for clinically significant changes (p<0.05) in tinnitus 
disturbance as measured by the THI at baseline and 1-year post-initial administration. A roadmap 
for statistical analysis of the data is included in this project. 
Discussion:  Anecdotal reports from clinicians at the IHC suggest significant improvements in 
subjective tinnitus as per patients taking the NH formulation.  A proper, evidence-based, 
framework for implementing and measuring subjective improvement in tinnitus percept is 
necessary for future research.  In addition to subjective reports, the distance traveled and cost out 
of pocket for the nutraceutical reveal a strong indication of perceived benefit. 
Conclusion:  The goal of this project is to implement an evidence-based clinical protocol at the 
IHC to standardize patient care in order to evaluate and statistically analyze the efficacy of the 
NH formulation on subjective tinnitus sufferers in the future.  Future research can use this project 
as a template to assess changes to tinnitus percept in patients taking the NH formulation.   
Key words: audiology, tinnitus, antioxidants, nutraceutical, clinical practice guideline, 
subjective tinnitus, bothersome tinnitus 
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INTRODUCTION 
Tinnitus and Hearing Loss 
Tinnitus is the conscious perception of an auditory sensation in the absence of a 
corresponding external stimulus (Baguley, McFerran, and Hall, 2013).  Patients with tinnitus are 
heterogeneous in tinnitus experience.  For example, tinnitus may be subjective or objective, high-
pitched or low-pitched, ringing or hissing, or have other varied clinical presentations.  According 
to the American Tinnitus Association (n.d.), subjective tinnitus, experienced by 99% of tinnitus 
sufferers, is the most common type and perceived by the patient only.  Meanwhile objective 
tinnitus, experienced by about 1% of patients, can be perceived by the clinician by auscultation 
(American Tinnitus Association, n.d.).  Generally, objective tinnitus comes in the form of 
pulsatile tinnitus, imitating the heartbeat (Baguley, McFerran, and Hall, 2013).   
Risk factors for tinnitus are vast, adding to its heterogeneity.  Hearing loss is the main 
risk factor for tinnitus, even though there are patients that present with tinnitus and normal 
audiometric data or others with hearing loss not reporting tinnitus (Baguley, McFerran, and Hall, 
2013).   Other factors Baguley et al. (2013) offer: environmental factors, such as noise exposure; 
medicinal factors including over-the-counter and prescription drugs that can be harmful to the 
ear and hearing, known as ototoxic drugs, including corticosteroids, loop diuretics, platinum 
based chemotherapy agents, and non-steroidal anti-inflammatory drugs (NSAIDs); and lastly 
pathologies of the ear such as otitis media, labyrinthitis, acoustic neuroma, Meniere’s disease, 
and otosclerosis are often accompanied by tinnitus. Thus, an unknown pathogenesis in addition 
to a plethora of presentations, lead to a very difficult to manage chronic disability.  Interestingly, 
according to Hobson, Chisholm, and El Refaie (2012), in 60% of patients that have had the 
auditory nerve severed secondary to tumor removal in acoustic neuroma, the presence of tinnitus 
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remained, suggesting “the fundamental importance of the central auditory pathways in the 
maintenance of the symptom, irrespective of the initial mode of generation being the cochlea or 
the vestibulo-cochlear nerve” (pg. 3). 
Severity is highly variable across tinnitus sufferers.  The research has shown no 
significant correlation between severity and the degree of hearing loss, nor has there been a 
correlation between the loudness of the tinnitus and how bothersome it is to the 
patient.  Depression, however, is highly correlated with the severity of tinnitus (Udupi et al., 
2013).  The disability generated by tinnitus depends “on primary psychological factors, such as 
difficulty in dealing with the problem” (Pinto et al., 2010, pg. 21).  The severity of annoyance 
due to tinnitus and the presence of psychiatric conditions is highly correlated as well. Most 
researchers agree, 10-15% of the population is affected by some form of tinnitus, and most are 
able to habituate to the sensation (Celik & Koyuncu, 2018; Ciorba et al., 2013).  Researchers, 
however, do not agree on the number of tinnitus sufferers unable to habituate to the sound which 
has been shown to lead to increased anxiety, social isolation, and depression.  This population is 
reportedly between 0.5% and 20% of patients (Baguley et al., 2013; Celik & Koyuncu, 2018; 
Pinto et al., 2010). Trevis, McLachlan, and Wilson (2018) reviewed the psychological effects in 
chronic tinnitus sufferers unable to adjust to the sensation.  The systematic review analyzed 
chronic tinnitus and its effect on emotional well-being (i.e. quality of life, depression and 
anxiety) and cognitive functioning.  Chronic tinnitus sufferers were found to have a clinically 
significant increase in depression and anxiety symptoms compared to healthy controls.  Some of 
the most notable impacts of tinnitus include poor sleep, social withdrawal, interference with 
work, suicidal thoughts, confusion, and worry (Trevis, McLachlan, and Wilson, 2016). 
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Anatomy and Physiology of the Ear & Oxidative Stress 
         The ear is divided into three anatomic parts:  outer, middle, and inner.  The outer ear 
includes the external, visible part of the ear, known as the pinna, and the ear canal.  The middle 
ear begins at the tympanic membrane, or ear drum, and houses the ossicles, or bones of the ear, 
the malleus, incus, and stapes.  Together, the outer and middle ear “form the sound conducting 
mechanism” (Alberti, 2001, p. 54).  The pinna collects sound and channels it into the ear 
canal.  The sound is then directed to the tympanic membrane, causing vibration and movement 
of the ossicles.  The inner ear “consists of the cochlea which transduces vibration to a nervous 
impulse and the vestibular labyrinth which houses the organ of balance” (p. 54).  The cochlea is 
“a bony tube filled with perilymph in which floats the endolymph filled membranous labyrinth” 
(p. 56).  The footplate of the stapes, in the middle ear, sits in the oval window of the cochlea.  
Vibration of the stapes footplate “vibrates the perilymph in the cochlea” (p. 56).  The basilar 
membrane, one of the separating structures between the perilymphatic and endolymphatic spaces 
in the cochlea, “responds resonantly to highest frequencies at its basal end nearest the oval 
window and to progressively lower frequencies” at its apical end, furthest from the oval window 
(p. 58).  “Four rows of hair cells lie on top of the basilar membrane, together with supporting 
cells”:  One row of inner hair cells (IHCs) and three rows of outer hair cells (OHCs).  It has “an 
abundant nerve supply carrying messages to and from the brain” (p. 57).  Therefore, vibration of 
the perilymph by the stapes footplate in the oval window is transmitted into a nervous impulse 
carried along the eighth cranial nerve, the vestibulocochlear nerve, “from the cochlea to the 
brainstem.  Here the nerve fibers reach nuclei where they relay with other nerve fibers…The 
fibers pass up the hindbrain to the midbrain and the cerebral cortex” (p. 58, 61).  “Any sound 
introduced at the oval window, by motion of the stapes, is transmitted along the basilar 
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membrane as a traveling wave until all of its frequency components reach their respective place 
of resonance where they stop and travel no further” (p. 60).  The inner and outer hair cells play a 
pivotal role in sound perception and transmission.  Damage to the cochlea via noise exposure or 
ototoxic medication, for example, will result in death of OHCs that are not regenerative.  “If the 
OHCs are damaged, they no longer contract in response to slight sounds and the IHCs are not 
stimulated…producing a hearing loss for low intensity sounds” (p. 61).  
As previously indicated, the pathogenesis of tinnitus is not yet clearly defined. In most 
patients, the development of tinnitus can be linked to damage to the cochlea.  Neri et al. (2006) 
evaluated the oxidative stress of 44 patients with idiopathic tinnitus and 25 healthy volunteers. 
They reported patients with idiopathic tinnitus presented a significant increment (p<0.05) of 
oxidative damage marker concentrations and plasma scavenger activity in jugular blood, 
accompanied by increased free radical concentrations.  Based on these findings, they concluded 
that oxidative stress is important in the pathogenesis of tinnitus. 
According to Pham-Huy, He, and Pham-Huy (2008), free radicals, or unpaired electrons, 
are highly reactive and are generated through the use of oxygen in the metabolism of certain 
compounds in the body’s daily processes.  Excessive production of free radicals can damage 
normal cells.  Environmental factors, including stress, smoke and pollution, and elevated iron 
and copper in the body can contribute to the creation of free radicals at an increased rate.  This 
excessive production causes oxidative stress, an inflammation to the cells that causes damage to 
DNA, RNA, cell membranes, proteins, and lipids.   
Koc et al. (2016) further explain reactive oxygen species (ROS) play a role in the 
pathogenesis of otlogic and neurologic diseases.  High concentrations of ROS can have cytotoxic 
and neurotoxic effects, resulting in damage to the auditory hair cells of the labyrinth and the 
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acoustic system.  Then, as Ciorba et al. (2013) suggest, it is reasonable to suppose “antioxidant 
drugs can reduce the amount of intracellular damages mediated by ROS” (p. 249).  The role of 
oxidative stress in certain inner ear disorders, such as Meniere's disease, noise-induced hearing 
loss, labyrinthitis, cisplatin ototoxicity and aminoglycoside ototoxicity is well known (Calabrese 
et al., 2010; Fujimoto and Yamasoba, 2014; Haase et al., 2016; Koc et al., 2016).  According to 
Haase et al. (2016), biochemical pathways are increasingly becoming the culprit for 
abnormalities “from the cortical level through the inner ear apparatus” (p. 56).  By understanding 
the effects of oxidative stress and free radicals on the inner ear, new biological options may be 
proposed in the management of tinnitus, especially for patients debilitated by the symptoms.  
 
Tinnitus Management 
Over the years, the research has shown inconsistent findings validating the efficacy of 
over-the-counter (OTC) vitamins, minerals, and supplements for the reduction of 
tinnitus.  Antioxidant therapies have included phospholipids, vitamins C and E, Ginkgo biloba, 
alpha lipoic acid, zinc, garlic, and lemon-bioflavonoid, among others (DiSogra, 2010).  The 
myriad clinical management strategies in attempts to alleviate tinnitus symptoms have ranged 
from “education and advice, relaxation therapy, tinnitus retraining therapy (TRT), cognitive 
behavioral therapy (CBT), sound enrichment using ear-level sound generators or hearing aids, 
and drug therapies to manage comorbid symptoms like insomnia, anxiety and depression” 
(Person et al., 2016, pg. 6). 
Drug therapies such as tricyclic antidepressants and serotonin-reuptake inhibitors have 
not been shown to reduce the tinnitus loudness or perception, but they have had a positive role in 
improving psychological distress (Baguley, McFerran, Hall, 2013).  According to Pirodda, 
Raimondi, and Ferri (2010), melatonin, used with patients suffering from tinnitus-related 
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insomnia, improves sleep even though the effect on tinnitus severity is minimal.  Increased 
intake of dietary components such as vitamin B, zinc, and magnesium have had poor quality of 
evidence and have been contradictory.  For example, Savastano et al. (2007) and Gopal et al. 
(2015) both reported positive findings.  Savastano et al. (2007) reported a decrease in reactive 
oxygen species (ROS) and tinnitus disturbance after 18 weeks of oral treatment with 
phospholipids and vitamins in a cohort of 31 patients reporting idiopathic tinnitus.  They 
analyzed measured changes in tinnitus loudness matching and subjective disturbance using the 
visual analogue scale (VAS).  Savastano et al. concluded patients experienced a decrease in ROS 
and tinnitus loudness and disturbance at the end of the trial (2007).  Gopal et al. (2015) found not 
only a subjective improvement in tinnitus distress in a case study of a female taking acetyl L-
carnitine (ALCAR) for thirty days, but they also noted improved post-treatment audiologic 
thresholds and a clinically significant decrease in tinnitus questionnaire scores on the THI, 14 
points pre-treatment to 4 points post-treatment.  On the other hand, Polanski et al. (2016) found 
no significant difference in pre- and 6-month post-treatment tinnitus questionnaires within 
subjects, nor between subjects in their four groups of patients taking either (1) Ginkgo biloba, (2) 
vitamin C with alpha lipoic acid, (3) papaverine hydrochloride with vitamin E, or (4) the placebo 
group.  
The door for research is open in the use of antioxidant approaches to relieving tinnitus 
distress in patients.  Although current research is still undecided on when and how to implement 
antioxidant therapy, there is strong data revealing a link between tinnitus and oxidative stress 
(Ciorba et al., 2013; Haase et al., 2011; Koc et al., 2016; Koca et al., 2018).  According to Pham-
Huy et al. (2008), oxidative stress can be counteracted naturally by antioxidants produced in the 
body, “endogenous antioxidants,” or it can be supplied through foods and supplements, 
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“exogenous antioxidants” (p. 92).  They state: “The roles of antioxidants are to neutralize the 
excess of free radicals, to protect the cells against their toxic effects and to contribute to disease 
prevention” (p. 92).  
Reactive oxygen species (ROS), as described previously, in large amounts can be 
hazardous to the body causing pathological disease (Pawlak-Osinska et al., 2018).  ROS are 
formed in the cochlear hair cells after exposure to cisplatin, aminoglycosides, salicylates, and 
noise, for example.  However, if in a homeostatic state, ROS are essential to body function, 
specifically in signal transmission inside the cell.  Endogenous antioxidants produced by the 
body, such as catalase, glutathione peroxidase, and glutathione S-transferase, can help to balance 
ROS activity.  An imbalance between ROS and endogenous antioxidants leads to pathological 
disease, including, but not limited to, damage to the inner ear like hearing loss and 
tinnitus.  Interestingly, in the Pawlak-Osinska et al. study (2018), the tinnitus subjects showed 
significantly lower levels of the endogenous antioxidants glutathione peroxidase and erythrocyte 
glutathione than the control group (p=0.026 and p=0.00, respectively).   
 Antioxidants obtained by food sources are known as exogenous antioxidants.   
Devasagayam et al. (2004) provide a comprehensive list of fruits, vegetables, legumes, oils, dairy 
products, and more that provide antioxidant support for flavonoids, polyphenols, carotenoids, 
and vitamins.  Haase et al. (2011) suggest preventive and protective benefits of antioxidants such 
as vitamin E, α-Lipoic acid, Coenzyme Q10, vitamin C and magnesium.  They further assert the 
combination of multiple antioxidants prevents the possibility of creating more free radicals in the 
body.  Haase et al. reminds us that although single agents may provide some benefit, more likely, 
the oxidation of an antioxidant creates free radicals (2011). 
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Two therapies used in managing tinnitus are cognitive behavioral therapy (CBT) and 
tinnitus retraining therapy (TRT).  CBT aims to alter the patient’s response to tinnitus, not the 
volume or perception.  Jun and Park (2013) explain the concept of CBT is to correct the negative 
perception, thoughts, and beliefs about the tinnitus, and replace them with “positive and realistic 
thoughts” (p. 101).  CBT does not aim to reduce the acoustic features of the tinnitus, rather the 
distress and handicap induced by the tinnitus.  TRT, on the other hand, uses a two-step process to 
reduce the perception, emotional associations, and negative reactions to the tinnitus.  Step one, 
described by Formby and Scherer (2013), involves “directive counseling,” similar to CBT, to 
“initiate the habituation process by neutralizing the negative and emotional reactions to the 
tinnitus” (p. 135).  Step two, they continue, involves the use of ear-level sound generators to 
enrich the sound environment and decrease the difference between the level of the tinnitus and 
the level of the ambient environmental sounds. 
Sound therapy, in its various forms, has been used in attempts to reduce tinnitus distress 
in chronic tinnitus patients.  According to Baguley, McFerran, and Hall (2013), after a treatable 
pathology associated with tinnitus has been excluded, such as cerumen or infection, standard 
care is to give an explanation of the situation, followed by sound therapy and intervention to 
reduce the distress.  Sound therapy includes hearing aids or sound generators to effectively mask 
the tinnitus.  In a systematic review by Hobson, Chisholm, El Refaie (2012), six trials of sound 
therapy masking studied 553 participants.  Hobson et al. found the studies failed to show strong 
evidence of the efficacy of sound therapy in changing the loudness or overall severity of tinnitus; 
however, some studies showed sound therapy devices were subjectively helpful in reducing 
levels of tinnitus annoyance and improved scores on questionnaires like the TRQ 
(2012).   Baguley et al. (2013) also discuss emerging sound treatments that not only mask 
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perception of the tinnitus, but are also effective as a therapeutic relaxant like the Widex Zen 
program, or one that reduces emotional arousal like the Neuromonics device (see also Tyler et 
al., 2017; Hanley et al., 2008).  At present, the evidence is still inconclusive on sound therapy as 
a tool to eliminate the perception of tinnitus; however, outcomes are strong for reducing its 
perception when in use.  
  
‘NHANCED Hearing Nutraceutical Formulation 
The current study aims to delve into an antioxidant micronutrient formulation created by 
Dr. Gerald Haase of the New Age Beverages Corporation, and formerly of the Premier 
Micronutrient Corporation (PMC).  The ‘NHANCED Hearing (NH), formerly Hearing Health 
(HH), formula claims to decrease the amount of free radicals in the body to increase effective 
immune function.  This NH formula includes Vitamins A, C, D, E, B6, B12, Calcium, Zinc, 
Magnesium, and other vitamins and antioxidants.  It is referred to as a nutraceutical, defined by 
Gupta et al. (2010) as a product that is derived from food sources with extra health benefits in 
addition to the basic nutritional value found in foods.  Gupta et al. (2010) elaborate: 
“Nutraceuticals are non-specific biological therapies used to promote general well-being, control 
symptoms, and prevent malignant processes” (p. 56).  The difference between a nutraceutical and 
the average over-the-counter (OTC) antioxidants is the specific and deliberate formulation that 
has an exact dosing schedule for best patient outcomes (Jain and Ramawat, 2013).    
The NH nutraceutical was created and marketed to preserve hearing status and combat 
free radicals in the hearing organ on a cellular level.  Dr. Gerald Haase, creator of the NH 
formula, worked closely with the United States Military, Department of Defense, and NASA on 
the nutraceutical.  According to Haase (2014), PMC formulations help reduce the amount of free 
radicals and inflammation, thereby increasing the immune system function.  In a 2011 
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publication, Haase posits a proper “combination of antioxidant supplementation may improve 
efficacy of standard therapy for some hearing disorders” (p. 57).  Singular antioxidants have their 
own positive properties for improving immune and hearing function; however, he notes, “single 
agents [antioxidants], when oxidized, act as a free radical” (p. 57), meaning, in an attempt to 
mitigate oxidative stress, one may be causing oxidative stress.  An important factor in the 
efficacy of the micronutrient is its specific and exacting dosing schedule.  Haase (2011) 
elaborates: “great fluctuations in antioxidant levels associated with only once a day or every 
other day dosing” may not be consistent enough to be effective (p. 57).  Therefore, “twice a day 
dosing maintains more constant levels to increase biologic effectiveness, protect the genetic 
machinery of the cell, and decrease cellular stress” (p. 57).  The pilot study for Hearing Health 
(now ‘NHANCED Hearing) revealed 7 patients out of 11 experienced a “clinically significant 
reduction in tinnitus grade,” monitored by scores on the Tinnitus Handicap Inventory, pre- and 
post-treatment (p. 59). 
Measuring Tinnitus: Questionnaires 
Baguley, McFerran and Hall (2013) point out since there is no objective test available for 
most tinnitus patients, except in the case of pulsatile tinnitus which can be detected by 
auscultation, other measures must be used to note changes in tinnitus perception and effects on a 
patient’s well-being.  They expand: Tests to match pitch and loudness of the tinnitus are difficult, 
relate poorly to the patient’s distress, and offer little to the subsequent management plan.  These 
perceptual measurements of tinnitus do not reflect how bothered the patient is.  Additionally, 
there is no linear relationship between the intensity of the tinnitus and how bothered the patient is 
by its perception; therefore, a self-report questionnaire will be the most effective tool for the 
current study. 
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Handicap from tinnitus can present as any or all of the following:  Stress, anxiety, 
depression, insomnia, concentration difficulty, and quality of life impairments (Baguley, et al., 
2013).  Questionnaires are generally used to assess the degree to which the patient is bothered 
and handicapped from the tinnitus (Fackrell and Hoare, 2014). Questionnaires also help to 
quantify and measure changes longitudinally.  Improved scores on a tinnitus questionnaire can be 
used as a counseling method to show the patient how a management technique is working over 
time. 
         There are many tinnitus questionnaires available, but they do not all measure the same 
aspects of the patient’s complaints (Fackrell and Hoare, 2014).  The six most common 
questionnaires are described here: 
1. Tinnitus Questionnaire (TQ) – created by Hallam, Jakes, and Hinchcliffe.  Fackrell and 
Hoare (2014) explain, this validated 52-item questionnaire measures tinnitus severity 
change and the relationship between different aspects of complaints and other 
psychological variables.  Answers are based on a 3-point scale of true, not true, or partly 
true.  The negative features of the TQ are the high demand on time; the majority of 
questions focus on emotional and cognitive aspects of the handicap; the three-point scale 
makes it difficult to notice small changes, and there is no grading system or minimal 
clinically important change score.  The Mini-TQ is a 12-question rapid version of the TQ.  
It shows greater treatment effects than indicated with the TQ.  The Mini-TQ also shows 
high item-total correlations, reliability and sensitivity to change. 
2. Tinnitus Handicap Questionnaire (THQ) -- Fackrell and Hoare (2014) continue, the THQ 
is a validated 27-item questionnaire that is sensitive to change in handicap over 
time.  The answers are on a scale of 1-100 allowing patients to see small changes in 
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handicap, making the THQ a sensitive outcome measure.  However, no grading scale has 
been developed and almost half of all statements relate to the psychological and 
emotional aspects of tinnitus handicap. 
3. Tinnitus Reaction Questionnaire (TRQ) -- Described by Fackrell and Hoare (2014) as a 
validated 26-item questionnaire that was developed to assess the effects of psychological 
distress on tinnitus and distinguish between its levels.  The TRQ lacks a recommended 
grading system or minimal clinically important change score.  However, the five-point 
Likert scale makes it more sensitive than the THI or TQ.  The TRQ measures similar 
constructs to those measured by more general questionnaires measuring depression or 
anxiety, making it an important tinnitus assessor due to the psychological effects it has on 
patients. 
4. Tinnitus Handicap Inventory (THI) – Fackrell and Hoare (2014) explain the THI was 
originally designed as a companion to the Hearing Handicap Inventory (HHI) and 
Dizziness Handicap Inventory (DHI) to complete a set of tools to quantify perceived 
handicap in a variety of hearing related conditions. This validated 25-item questionnaire 
measures the impact of tinnitus on everyday function using a three-point scale, yes, 
sometimes, or no.  In contrast to some other tinnitus questionnaires, the THI has a 
grading system categorizing tinnitus handicap based on the patient’s responses:  slight, 
mild, moderate, severe, or catastrophic.  Additionally, a minimal clinically important 
change score of 7 points has been determined to measure treatment related changes.  
Similar to other tinnitus questionnaires, the THI focuses on the psychological and 
emotional aspects of the handicap. 
 13 
5. Tinnitus Functional Index (TFI) – Fackrell and Hoare describe this 25-item questionnaire 
that discriminates between levels of distress, and provides a responsive measure of 
treatment related change.  The answers are on a scale of 0-10, which allows for the 
detection of small changes over time.  Like the THI, the TFI has a grading system and a 
minimal clinically important change score.  Additionally, the questions in the TFI are 
more evenly weighted across different aspects of tinnitus handicap than in other 
questionnaires. 
6. Self-efficacy for Tinnitus Management Questionnaire (SETMQ) – Smith and Fagelson 
(2011) describe this 40-item questionnaire that allows patients to rate their answers on a 
percentage scale from 0-100% in intervals of 10 percentage points.  The questionnaire 
rates the patient’s self-efficacy in various areas of tinnitus management.  The areas 
include routine tinnitus management, emotional response to tinnitus, internal thoughts 
and interaction with others, tinnitus concepts, and use of assistive devices. 
 
Tinnitus Management – An International Review 
Fuller et al. (2017) performed a systematic review of current clinical guidelines for 
tinnitus in Denmark, Sweden, Germany, the Netherlands, and the United States.  The review 
discusses both assessment guidelines across the countries and management guidelines.  Fairly 
consistently, the guidelines suggest physical examination by an otolaryngologist or other related 
professional and a hearing examination which includes the complete audiologic evaluation 
(CAE).  Some guidelines suggest other audiologic assessments like auditory brainstem response 
(ABR), loudness discomfort levels (LDL), and otoacoustic emissions (OAE), though these are 
not consistent across countries.  A tinnitus questionnaire is always indicated, regardless of 
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country.  The most popular questionnaires, according to the guidelines, are the THI and 
TQ.  Also, a psychological assessment is indicated, to include investigations of how the tinnitus 
is affecting the patient’s daily life and comorbid symptoms. 
The tinnitus management recommendations similarly remain consistent across countries 
(Fuller et al., 2017).  No medical treatments are indicated for tinnitus specifically; however, 
recommendations are present for comorbidities, like depression, sleep, or anxiety.  Audiological 
interventions strongly recommend the use of hearing aids for tinnitus patients with hearing loss, 
while TRT is recommended as a sound therapy for patients without hearing loss in all guidelines 
except in Germany.  Lastly, CBT is strongly recommended as a psychological therapy across the 
board.  
Ogawa et al. (2019) released clinical practice guidelines for diagnosis and treatment of 
chronic tinnitus following the guidelines set forth in Fuller et al. (2017).  They recommend the 
use of a validated tinnitus questionnaire, namely the THI which has been translated into 
Japanese, pure tone audiometry, pitch matching, and loudness balance testing.  Imaging is 
recommended by Ogawa et al., particularly for patients suffering from unilateral or pulsatile 
tinnitus.  Lastly, the Japanese guideline supports TRT and CBT as treatment and management 
techniques for chronic tinnitus.  A disadvantage for CBT at this time in Japan is the minimal 
number of facilities offering CBT with trained experts, but they find it to be a cost-effective 
treatment with no side effects.   
Tunkel et al. (2014) created a comprehensive clinical practice guideline for the American 
Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF).  The 
audiologic test battery recommended includes pure tone air conduction thresholds 250Hz 
through 8000Hz including interoctave frequencies as deemed necessary by the clinician, bone 
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conduction thresholds 250-4000Hz, speech recognition thresholds, word recognition scores, 
immittance measures to include contralateral acoustic reflex thresholds (ARTs) 500-4000Hz, 
ipsilateral ARTs 500-4000Hz, and acoustic reflex decay at 500 and 1000Hz.  Tunkel et al., 
similar to Ogawa et al. (2019), recommend sound therapy and CBT for patients with persistent, 
bothersome tinnitus.  On the other hand, Tunkel et al. strongly advise against the use of dietary 
supplements including Ginkgo biloba, melatonin, zinc, or other supplements for patients with 
persistent, bothersome tinnitus.  The authors report a lack of proven efficacy in randomized 
clinical trials. 
The Tinnitus Research Initiative (TRI) provides a broad flow-chart for clinical use to 
assist in managing the chronic tinnitus patient (Biesinger et al., 2011).  The guideline proposes 
not only the case history and audiologic test battery, but it suggests psychoacoustic measures 
including pitch matching, loudness matching, minimum masking levels, residual inhibition, and 
loudness discomfort/growth tests.  Although the current research project has determined 
psychoacoustic measures to be difficult and poorly related to patient’s distress, the TRI considers 
the psychoacoustic measures may offer diagnostic value in the counseling process for the chronic 
tinnitus patient (Baguley et al., 2013; Biesinger et al., 2011).  Additionally, psychoacoustic 
measures may also aid in hearing device programming, specifically the loudness discomfort 
levels. 
In all, the above guidelines for tinnitus management are important for developed and 
developing countries to implement for tinnitus patients.  The current project proposes the 
adoption of recommendations to better manage tinnitus patients, especially those with 
bothersome tinnitus.  Most importantly, the assessment of tinnitus patients must include a CAE, 
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tinnitus questionnaire and examination by an otolaryngologist.  The management, as proposed by 
the current study, will include dispensing of the NH nutraceutical formulation.  
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METHODOLOGY 
  
The aim of this research project will be to measure the subjective changes in tinnitus 
perception while using the NH nutraceutical.  As seen in the literature review, the THI and TFI 
are the only tinnitus questionnaires that have a grading system and minimal clinically important 
change score; however, the TFI, according to Fackrell and Hoare (2014), has not undergone 
formal validation.  Therefore, changes will be measured by comparing the responses to the 
Tinnitus Handicap Inventory (THI) at baseline, then in 3 month intervals at 3-, 6-, and 9-months’ 
post-administration, and 1-year post-administration.  This will make it possible for researchers to 
note changes in tinnitus perception and the level of distress for patients at periodic follow-up 
appointments.  The research hypothesizes using the NH formula will decrease the perception of 
subjective tinnitus.  Furthermore, the research will analyze if any change in tinnitus perception 
remains over an extended period of time, for example a 6-month or 1-year period, and if 
cessation of the nutraceutical has any positive or negative effects on the percept.  
The study will be designed as a retrospective chart review.  Data will be collected from 
the International Hearing Centre (IHC) in Lagos, Nigeria.  Anecdotal evidence from 
Audiologists and Pharmacists at the IHC suggest improvements in subjective tinnitus severity as 
per patient report, therefore, the research will examine the charts of patients to whom the 
nutraceutical has already been administered.  Data collected will be redacted patient files 
containing only the following information: Gender, age, audiometric data including type and 
degree of hearing loss, if any, description and duration of the tinnitus, the case history related to 
hearing and tinnitus, and a pre- and post-administration tinnitus handicap inventory (THI) 
questionnaire.  A minimum of 30 patient charts will be reviewed in order to make statistically 
significant claims of correlative effects of the nutraceutical formulation on subjective tinnitus 
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perception.  In light of the within-subjects design of the study, gender and age will not be 
controlled for in data collection.  Furthermore, there are discrepancies in the literature whether 
gender or age have a significant effect on tinnitus.  Seydel et al. (2011) found women to be more 
emotionally affected by tinnitus using the Tinnitus Questionnaire (TQ) and four other 
questionnaires investigating perceived stress, coping, and sense of coherence measures.  
Regardless of age, Seydel et al. found women to have less loud tinnitus, compared to their male 
counterparts, measured by tinnitus loudness matching (2011).  The study found age and gender 
to be important factors in psychometric outcomes.  On the other hand, Udupi et al. (2013) 
reported no significant differences between gender or age and tinnitus severity.  The authors 
found correlation between depressive symptoms and tinnitus severity, as has been previously 
discussed.   
The NH formula composition is seen below in Table 1.  According to the specified 
dosing schedule, patients are advised to take two pills, two times daily.  This, as suggested by Dr. 
Haase, will maintain antioxidant levels in the blood for increased efficacy and decreased cellular 
stress (2011).  The dosage will remain constant, with no tapering instructions.  
 
Table 1. List of ingredients New Age Beverages Corporation NH Formula. 
Ingredient Amount Per 
Serving 
% Daily 
Value 
Vitamin A 5500 IU 183% 
Vitamin C 250 mg 278% 
Vitamin D 200 IU 25% 
Vitamin E 200 IU 935% 
Thiamin 4 mg 333% 
Riboflavin 5 mg 385% 
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Niacin 30 mg 188% 
Vitamin B6 5 mg 294% 
Folic Acid 200 mcg 50% 
Vitamin B12 10 mcg 417% 
Biotin 200 mcg 667% 
Pantothenic Acid 10 mg 200% 
Calcium 60 mg 5% 
Magnesium 100 mg 24% 
Zinc 15 mg 136% 
Selenium 100 mcg 182% 
Chromium 50 mcg 143% 
Proprietary Blend – L-Cystine, L-Carnitine, Alpha Lipoic 
Acid, Co-Enzyme Q10 
575 mg Unspecified 
 
         Inclusion criteria for patient data will include healthy adults age 18 and above.  Since 
tinnitus can affect both normal hearing and hearing impaired patients, the audiometric criteria 
will be inclusive of both.  In order to be a candidate, the patient must have a history of chronic 
tinnitus lasting 6 months or longer.  Although it has been established that tinnitus symptoms are 
heterogeneous in presentation and percept, the research will be inclusive of the following 
percepts: “ringing,” “buzzing,” “hissing,” “crickets,” “roaring.”  The patient must be taking the 
nutraceutical formulation for 3 months or longer, as recommended.  The dosing schedule is 
specific and imperative to follow; therefore, patients who have not taken two pills, twice daily, 
will be excluded.  Appendix 1 is a checklist for use by the clinician to abide by the 
inclusion/exclusion criteria.   
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         Exclusion criteria will include any patients younger than 18 years old.  A tinnitus 
described as “pulsatile” or “clicking” will be excluded.  Additionally, any previous or current use 
of tinnitus treatment, including, but not limited to, antioxidants, antidepressants, melatonin, TRT 
or CBT, will be cause for exclusion.  The patient must also complete the informed consent form, 
if the patient refuses, s/he will be excluded from the study.  
 Further audiologic exclusion criteria include abnormal otoscopic evaluation, including 
perforated tympanic membrane or a mass observed through the tympanic membrane.  Patients 
with active middle ear disease or conductive hearing loss are excluded, including abnormal 
tympanograms classified as Type B, meaning no peak due to perforation, effusion, or otherwise.  
Additionally, any confirmed retrocochlear pathology (e.g. acoustic neuroma) or diagnosis of 
Meniere’s Disease will be cause for exclusion.  Lastly, any treatment with aminoglycoside 
antibiotics, platinum-based chemotherapy, quinine, or otherwise ototoxic medication will lead to 
exclusion from the study.  As seen in Baguley, McFerran, and Hall (2013), the above mentioned 
otologic findings can be accompanied by tinnitus, which may or may not resolve with treatment.  
A patient with impacted cerumen upon otoscopy will be excluded from the study if the tinnitus 
resolves after cerumen removal, otherwise they will be included.  Patients with any of the above 
will be excluded from the current study to minimize confounding factors.    
         After approval by the International Review Board (IRB) at the City University of New 
York (CUNY), the pharmacist employed at the International Hearing Centre in Lagos, Nigeria 
indicated to the researchers a lack of consistent charting for the NH tinnitus patients.  The 
redacted charts received by the researchers included audiograms, general case history forms, and 
a formal report by the lead audiologist.  However, a majority of the charts did not include a pre-
administration tinnitus questionnaire or any follow-up visit questionnaires.  Due to the 
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inconsistent charting and lack of protocol for tinnitus patient charts, this Capstone project will 
propose an evidence-based guideline for audiologists and pharmacists to follow at the IHC, as 
well as, for future use by clinicians and healthcare professionals involved with the administration 
of the NH nutraceutical formulation.  
         The case history form (Appendix 2) to be used for future patients to whom the NH 
formula will be administered must contain the following information, suggested by the American 
Speech-Language-Hearing Association (n.d.), completed by the Audiologist and patient at the 
initial visit: 
• Tinnitus description -- the patient will be asked to describe their tinnitus in the following 
ways: 
o Presentation - referring to a description such as a ring, buzz, click, hiss, heartbeat, 
chirp, or any other sound it may be akin to.  
o Onset and duration of the tinnitus 
o Pitch - patient may describe as high- or low-pitch, or relate it to a household 
sound 
o Loudness - patient can confirm if the tinnitus is louder than conversation, noticed 
only in the quiet of the home, or otherwise 
o Maskability – an account of any sounds or activities that dampen the tinnitus 
• Medical history – other diagnoses and lab results from other health professionals 
• Provoking and alleviating factors for tinnitus percept 
• History of noise exposure or trauma 
• Otologic or vestibular issues 
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• Other concerns including anxiety and depression - A patient scoring greater than 36 on 
the THI will be administered the Beck Anxiety Inventory (BAI) -- a 21-item 
questionnaire used in the clinical setting to measure anxiety levels in adolescents and 
adults.  A score > 16 on the BAI signifies a moderate level of anxiety or greater and will 
lead to referral to a medical professional, i.e. psychiatrist or clinical psychologist (Grant, 
2011; Biesinger et al. 2011).  Salviati et al. (2013) determined a score greater than 36 
points on the THI was correlated with a psychiatric disorder in tinnitus patients.  Almost 
half of the tinnitus patients in their study were found to have either anxiety disorder, 
adjustment disorder, bipolar disorder, or other mental health disorders (Salviati et al., 
2013). 
 
At the initial visit, audiometric data must include the following objective and subjective test 
measures: 
• Pure tone air conduction thresholds: Octave frequencies 250-8000Hz and 
interoctave frequencies 3000 and 6000Hz.  Langguth et al. (2007) state pure tone 
audiometry up to 8kHz is necessary for all patients, with recommendations of high 
frequency audiometry (HFA) thresholds up to 12kHz.  In studies of noise induced hearing 
loss, the highest percentage of hearing loss is present between 3000 and 8000 Hz, 
including 6000Hz (Hwang et al., 2009).  For this reason, 3000 and 6000 Hz will be 
included in audiologic assessment, due to the close link between noise exposure, hearing 
loss, and tinnitus.  Interoctave frequencies between 500 and 2000Hz will be assessed only 
if a difference of 20dB or more is present between adjacent frequencies (Schlauch and 
Nelson, 2009).  The IHC does not have the equipment necessary to perform high 
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frequency audiometry, therefore, HFA will not be part of the recommended audiologic 
evaluation.   
• Pure tone bone conduction thresholds:  Octave frequencies 500-4000Hz - unmasked 
bone conduction thresholds will be measured at the four octave frequencies between .5-
4kHz.  An air-bone gap of more than 10dB will require masking to determine the nature 
of the hearing loss (Schlauch and Nelson, 2009).   
• Immittance results: Rosowski and Wilber (2015) recommend 226 Hz tympanograms as 
determined by the ANSI S3.36 standard; ipsilateral and contralateral acoustic reflex 
thresholds (ARTs) measured at 500, 1000, and 2000 Hz in 5 dB steps with a 0.02 mmho 
stimulus-related immittance change [4000 Hz will not be assessed as ARTs at this 
frequency are often elevated (Gelfand, 2009)]; and reflex decay measured at 500Hz for 
10 seconds at 10dB SL above the ART in the contralateral stimulus mode (Gelfand, 
2009). 
• Distortion product otoacoustic emissions results - 1.5-12kHz - Langguth et al. (2007) 
recommend OAEs as part of the audiologic assessment.  Since HFA is not possible at 
IHC, DPOAE results up to 12kHz will be implemented as part of the proposed protocol 
to assess cochlear outer hair cell function in the ultra-high frequencies.   
The audiological evaluation will be completed at 6-months and 1-year post-initial administration 
of the NH formula to measure stability of hearing levels.  Any significant decreases in auditory 
thresholds (15 dB HL or more) will result in temporary cessation of the NH formula, until 
medically cleared by an otolaryngologist.  Haase et al. (2011) report the formulation to have 
neuroprotective properties, and deny any adverse side effects due to toxicity.  The NH formula, 
as mentioned, has a specified dosing schedule meant to maintain antioxidant levels in the blood 
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at safe levels.  As in other research of ototoxic medications, cessation of therapy is indicated if 
significant health changes occur (e.g. changes in hearing), therefore, the recommendation for the 
clinical protocol at the IHC is to regularly monitor hearing thresholds and to stop use of the 
nutraceutical if any significant changes are noted (Wilcox and Artz, 2007). 
The Tinnitus Handicap Inventory (THI), seen in Appendix 3, must be filled out by the 
patient at the first visit to determine the severity of tinnitus.  Additional questions that may be 
included for informational purposes will be answered with yes, sometimes, or no.  The final 
question will be answered with a percentage score.  See the following: 
• My tinnitus has led me to avoid social situations (Wilson et al., 1991) 
• My tinnitus has led me to think about suicide (Wilson et al., 1991) 
• My tinnitus contributes to a feeling of general ill health (Kuk et al., 1990) 
• I have a healthy outlook on tinnitus (Kuk et al., 1990) 
• I have support from my friends and family regarding my tinnitus (Kuk et al., 1990) 
• What percentage of your time awake were you consciously aware of your tinnitus? 
(Meikle et al., 2012) 
The THI and additional questions will then be re-administered at the 3-month, 6-month, 9-month 
and 1-year follow up visits.  In other studies of antioxidant usage for treatment and maintenance 
of disease, researchers followed up with patients every three months to monitor status.  For 
example, Gutzmann and Hadler (1998) and Weyer et al. (1997) followed patients with 
Alzheimer’s Disease for two years with follow up visits every 3 months to reassess results on the 
Alzheimer’s Disease Assessment Scale (ADAS), the Mini-Mental State Evaluation (MMSE) and 
the Digit Symbol Substitution Test (DSS).  
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RESULTS 
 
 Pre-treatment and 1-year post-treatment audiologic results will be compared in a table 
including pure tone audiometric thresholds, distortion product otoacoustic emission results, 
tympanometry and acoustic reflex testing.  It is important to note, although the patient will have 
had an audiologic evaluation at the 6-month interval, post-treatment, the results section will only 
assess the 1-year post-treatment results.  The purpose of the research is to assess the clinical 
implications of the NH formula on tinnitus perception.  Audiologic evaluations at 6-month 
intervals are explicitly for monitoring hearing status in patients taking the formula.  As 
previously indicated in ototoxic drug administration research, it is important to monitor stability 
of auditory thresholds and cease therapy if adverse health changes occur (Wilcox and Artz, 
2007).  Here, any significant decrease in auditory thresholds of 15 dB HL or more will be cause 
for temporary cessation of antioxidant therapy until medically cleared by an otolaryngologist.    
 The primary outcome measure will be the THI, which will be administered at 3-month 
intervals.  The THI score will be compared to the baseline, pre-treatment score at each interval.  
The use of pre-administration and post-administration questionnaires allows for each patient to 
serve as their own control.  The hypothesized expectation is a statistically significant 
improvement in THI score and subjective improvement in tinnitus percept to the patient after 1-
year of NH administration.  The null hypothesis is no improvement in THI score or subjective 
improvement after 1-year NH administration.  The research will aim to assess if the results at 3-, 
6-, 9-months, and 1-year post-administration have a cumulative effect, suggesting the percept 
continues to decrease in severity to the patient; or if there is a ceiling effect to the treatment that 
will plateau at a point in time.   
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 Statistical analysis will be used to determine any differences in pre- and post-
administration THI scores.  Clinical significance, as discovered by Zeman et al., is defined as a 
change in the THI of 7 points or greater (2011).  For comparison of serial measurements, i.e. 
before and after, within patients, the non-parametric Wilcoxon Signed Ranks Test will be 
used.  Statistical significance will be defined as a p-value < 0.05.   
The research outcomes will also be analyzed for any significant differences between 
subjects.  Of particular interest could be age, gender, or description of tinnitus percept.  To assess 
any between-subjects results, the researchers would use an independent samples / unpaired t-
test.  Age may be divided into an older and younger group in order to make the analysis.  These 
groups may be determined once participants have been identified.  The tinnitus percepts, too, 
may be separated into groups dependent on patient reports.  Statistical significance, again, will 
be determined with a p-value < 0.05. 
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DISCUSSION 
 
Implementing a clinical protocol for dispensing the NH formulation to patients reporting 
subjective tinnitus is necessary to provide an evidence-based guideline for clinicians at the IHC. 
Such guidelines could serve to improve patient care and create a uniform evaluation of tinnitus 
patients.  The anecdotal reports of clinicians and pharmacists at the IHC indicate subjective 
improvement in tinnitus severity for patients suffering from tinnitus.  A mandated clinical 
protocol will allow patients to receive the same standard of care, as well as allow researchers to 
quantitatively assess this particular management strategy.  The present research evaluated a 
systematic review of clinical practice guidelines for Denmark, Germany, the Netherlands, 
Sweden, and the United States “Different teams, same conclusions,” “Clinical practice guideline 
for diagnosis and treatment of chronic tinnitus in Japan,” and “Clinical practice 
guideline:  Tinnitus,” (Fuller et al., 2017; Ogawa et al., 2020; Tunkel et al., 2014).  Additionally, 
the Tinnitus Research Initiative lends a flowchart for patient management to be implemented on 
an international level (Biesinger, 2011).  Across the diverse guidelines, the most common 
recommendations were highlighted in this project:  a comprehensive evaluation including pure 
tone air and bone audiometry, acoustic reflex thresholds and reflex decay, speech reception 
thresholds, word recognition scores, and tympanometry; a complete case history to determine 
onset and duration of tinnitus, description of tinnitus percept, how bothersome it is to the patient, 
and the ability to mask the tinnitus; a completed Tinnitus Handicap Inventory and Beck Anxiety 
Inventory (if indicated); and evaluation by an otolaryngologist if case history or audiological 
evaluation indicate. 
According to Murad (2017), clinical practice guidelines can assist clinicians in making 
appropriate decisions in regards to patient assessment and management.  One of the most 
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important benefits of using systematically reviewed guidelines, such as the “Clinical practice 
guideline: Tinnitus,” is improved patient care.  Murad reports guidelines aim to encourage 
proven interventions and discourage ineffective ones, thereby improving quality of care 
(2017).  He further posits guidelines can lessen disparities and reduce unnecessary variations in 
care.  It is important to recall the heterogeneity in chronic tinnitus patients.  Clinical practice 
guidelines help to introduce an evidence-based standard of care across the field created by 
professionals who have considered the benefits and risks of diagnostic measures and 
management techniques.  Therefore, the protocol proposed to the IHC for use with their tinnitus 
patients is meant to create a consistent level of quality care by the healthcare professionals.  The 
protocol aims to implement consistent charting efforts to aid in differential diagnosis and 
outcome measurement.  For instance, the current charting contained incomplete tinnitus 
questionnaires and scant case history responses.  With the complete aforementioned information, 
the current study could have analyzed the tinnitus questionnaires pre- and post-administration of 
the NH nutraceutical to investigate if the anecdotal reports of patients and clinicians equated to 
clinically significant improvements.   Although the consensus across published clinical practice 
guidelines is negative toward dietary supplements and nutraceutical formulations, Woolf et al. 
(1999) reminds us of some limitations to guidelines.  They suggest only a small number of 
studies are well-designed with good generalizability.  The evidence is sometimes lacking or 
misinterpreted.  Therefore, and perhaps ironically, it is imminent the IHC implements consistent 
charting so research may analyze the outcomes of the NH nutraceutical and its seemingly 
positive effects on chronic tinnitus patients.   
Research indicates positive outcomes in tinnitus resolution when the primary disease is 
treated.  For instance, in cases of tinnitus secondary to cerumen impaction, otitis media, or 
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temporomandibular joint disorder, removal of cerumen, antibiotics, or neuromuscular splints 
have shown improvement in subjective tinnitus, respectively (Attanasio et al., 2015; Baguley et 
al., 2013).  However, in cases of acoustic neuroma patients, subjective tinnitus improved in 16% 
of patients and worsened in 29% of patients after resection of the tumor (Fahy et al., 2002).  
Additionally, tinnitus symptoms secondary to ototoxic drug administration have been shown to 
reduce in severity with drug cessation (Attanasio et al., 2015).  The current study aims to 
implement clinical practice guidelines at the IHC, where health professionals have taken a 
therapeutic approach to tinnitus with uncertain etiology.  Elgoyhen and Langguth (2011) 
mention, there is an unmet need for a drug therapy aiming to eliminate, or at the very least, to 
produce a small, but significant change to the tinnitus percept.  The NH formula, described by 
Haase et al. (2011) as the HH formula, provides a broad spectrum of antioxidants and their 
derivatives combined to impact oxidative damage and inflammation and to provide 
neuroprotection in hearing disorders.  Previous research of antioxidants and tinnitus has revealed 
contradictory findings.  As previously reviewed, the most efficacious pharmacotherapies, thus 
far, have been those combating comorbidities such as insomnia, depression, and anxiety.  Here, 
the NH formula incorporates a comprehensive, multiple micronutrient strategy, rather than the 
single, limited combination approaches used in the past.  Therefore, controlled clinical research 
must be completed to investigate the proposed benefits of the NH formula.  Furthermore, a 
complete, clinical protocol needs to be implemented to allow for this research.  The implications 
of positive findings secondary to the proper use of the NH formula are tinnitus relief for sufferers 
of chronic tinnitus and limited side effects.  Some previous drug therapies that have had adverse 
side effects include: anti-epileptic drugs, benzodiazepines, intratympanic gentamicin and steroid 
injections, lidocaine, and vasodilators (Smith, Zheng & Darlington, 2005).  Additionally, Ginkgo 
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biloba, particularly when taken with drugs like aspirin, can increase the risk of bleeding due to 
its vasodilatory effects (Smith, Zheng & Darlington, 2005).  Haase et al. (2011) reviewed the 
dosage of the ingredients in the NH, formerly HH, formula.  Toxicity was reported in Vitamins 
A and D and the mineral selenium at high doses; however, the dosage in the NH formula is 
below levels associated with adverse side effects.  The remaining ingredients are all considered 
to be non-toxic (Haase et al., 2011).  Thus, the nutraceutical formulation has the ability to be a 
positive incorporation into the tinnitus management portfolio for clinicians.  The benefits 
outweigh the risks of the NH formula and as Elgoyhen and Langguth (2010) mention, patients 
are desperate for a drug therapy that could reduce or completely stop this subjective sound.    
 This desperation has led patients to search tirelessly for treatments, both medicinal and 
behavioral, that can help alleviate the negative associations brought on by the tinnitus.   
According to the IHC in Lagos, Nigeria, patients have reported subjective benefit to tinnitus 
perception associated with taking the NH formula.  This has placed a high demand on the 
nutraceutical.  Even though the nutraceutical sells for 14,000 Naira (N14,000), patients will 
come from distant states or neighboring countries, as far as eighteen hours’ drive, to acquire the 
formulation (I. Okeke, personal communication, January 20, 2020).  This amounts to about $40 
according to the most current exchange rates (XE Currency Converter, 2020).  However, it does 
not take into account the cost of living and salary differential between the United States and 
Nigeria.  The average Nigerian monthly salary, according to Trading Economics (2018) is about 
N43,000, while the average American monthly salary is about $3600, according to the Bureau of 
Labor Statistics (2020).  Therefore, if one bottle of NH costs N14,000, this is about ⅓ of the 
average Nigerian’s monthly salary, which then amounts to almost $1200, ⅓ of the average 
American’s salary, for one bottle, or one month’s supply.  The distance traveled and the cost 
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paid, in tandem, lend themselves as strong indicators that this nutraceutical is helping patients to 
deal with a chronic problem.  Unfortunately, there is no health insurance system in place that 
covers the cost of a supplement such as NH, nor does one exist that covers the cost of diagnostic 
evaluations.   
There is currently a dysfunctional health insurance system in Nigeria called the Nigerian 
Health Insurance Scheme (NHIS).  Created about 10 years ago, the NHIS attempted to provide 
prepayment plans to Nigerian citizens (Nsofor, 2018).  According to Okpani and Abimbola 
(2015), only about 5% of Nigerians have prepaid healthcare through social and voluntary private 
insurance; an additional 20% of Nigerians receive healthcare through the federal government if 
they are federal employees or the family members of federal employees; and the remaining 70% 
of Nigerians are uninsured and pay out of pocket for healthcare.  They further explain: public 
sector healthcare facilities in Nigeria are located in each of the 36 states and are considered not-
for-profit organizations.  Even though the cost is significantly less than private sector facilities, 
Okpani and Abimbola note a perception of poorer quality care in the public sector facilities 
(2015).  The IHC is considered part of the private sector health facilities and sees a majority of 
its patients paying out of pocket.  The cost, according to Dr. Okeke, founder and lead audiologist 
at the IHC, for a basic hearing evaluation including pure tone air conduction and bone 
conduction thresholds, speech reception thresholds, word recognition scores, and tympanometry 
including acoustic reflex thresholds, is N14,000 (I. Okeke, personal communication, January 20, 
2020).   
The IHC and other healthcare facilities and practitioners are regulated by the Nigerian 
government.  Okpani and Abimbola (2015) explain the structure and responsibilities of the 
government as it pertains to healthcare and pharmaceuticals.  The government is separated into 
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three branches:  federal, state, and local.  Of note, the federal government provides support to 
state and local government on health program planning and implementation, health policy 
making and priority setting, and setting minimum standards for training and licensing of health 
workers.  The Federal Ministry of Health (FMOH) notably regulates activities of healthcare 
practitioner groups and regulates pharmaceutical and food products.  The NHIS, an agency of the 
FMOH, regulates healthcare and accredits HMOs.   
 A separate entity from the federal government is the National Agency for Food and Drug 
Administration and Control (NAFDAC).  The NAFDAC, similar to the United States Food and 
Drug Administration (FDA), imposes guidelines on food, drugs, medical devices, herbals and 
cosmetics, among other items (NAFDAC, 2016).  According to Dr. Okeke, the registration 
process for proper licensing and distribution of the NH nutraceutical formulation requires 
compliance with several directives:  evidence and scientific studies of NH, inspection of the 
manufacturer’s location, and presence of a superintendent pharmacist for dispensation of the 
nutraceutical (I. Okeke, personal communication, January 20, 2020).  The professional role of 
pharmacists in Nigeria has evolved from a focus on preparation, dispensing, and sale of 
medications to one where the pharmacists are present to assist the public in education and patient 
monitoring for the best possible results (Erah, 2003).  Therefore, the role of the pharmacist at the 
IHC helps to ensure proper protocol in dispensing the NH formula for all patients seen.  The 
above evidence of patients traveling from afar and paying up to ⅓ their salary to obtain the NH 
nutraceutical is important to remember when considering perceived benefit from the formula.  It 
appears there is a benefit that far outweighs the cost and accessibility.   
 A recent randomized, single-blind clinical trial by Petridou et al. (2019) assessed the use 
of antioxidant supplementation in a group of chronic tinnitus sufferers compared to matched 
 33 
placebo controls in Greece.  Although the authors do not name the supplement, the ingredient 
list, found in Appendix 4, is very similar to that of NH.  The study added a supplement of alpha-
lipoic acid (ALA) to participants' daily intake, which is also found in the proprietary formula of 
NH.  Participants were followed for three months, assessing pre-treatment and post-treatment 
results on pure tone audiometry 250-12,000Hz, pitch and loudness psychoacoustic matching 
measurements, and three questionnaires: THI, Tinnitus Functional Index (TFI), and the visual 
analogue scale (VAS) for tinnitus disturbance.  After three months, the antioxidant group was 
found to have significantly lower scores on THI, VAS, and TFI compared to the placebo group.  
This, the authors suggest, means the antioxidant supplementation was effective in alleviating 
patients from tinnitus-related distress compared to the placebo group.  It is promising to see a 
formula with a similar list of ingredients has proven effective in a well-designed clinical trial.   
 In October 2019, a press release from New Age Beverages Corporation announced the 
launch of the NH formula in Japan, following a test-market release in Korea (New Age 
Beverages Corporation, 2019).  It appears Japan does have a regulatory body, similar to the U.S. 
FDA, called the Pharmaceutical and Food Safety Bureau (PFSB), which is part of the larger 
Ministry of Health and Welfare (MHW) (Nagata & Rafizadeh-Kabe, 2002).  The PFSB, 
according to Nagata and Rafizadeh-Kabe, is responsible for approval review and regulation and 
decision-making for the MHW (2002).  On the report of the authors, western medicines are seen 
as potentially dangerous by the Japanese public.  This indicates there may be some positive 
outcomes derived in clinical trials that have encouraged the public to adopt the NH formula for 
tinnitus management.   
 For patients suffering from bothersome, chronic tinnitus, a combination of the NH 
antioxidant nutraceutical with another form of therapy may also prove efficacious.  For example, 
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the addition of tinnitus retraining therapy may help to combine a central auditory therapy with 
the peripheral auditory therapy of the nutraceutical.  Of the many theories surrounding the 
pathophysiology of tinnitus, one that has continued to be particularly interesting is the 
involvement of the limbic system.  Rather than a peripheral auditory system dysfunction, limbic 
system involvement proposes central dysfunction.  Michel et al. (2015) suggest the limbic 
system has an important role in learning and memory function, as well as generation, integration, 
and control of emotions and behavioral responses.  It seems reasonable that a system involved 
with behavioral responses has an effect on a patient’s awareness and disturbance by this phantom 
auditory percept.  Michel et al. explain further the dysfunction of the limbic regions are 
implicated in etiology of mental disorders like anxiety and depression (2015).  The link between 
chronic tinnitus and anxiety or depressive symptoms has been repeatedly investigated, and in 
their 2018 systematic review and meta-analysis, Trevis, McLachlan, and Wilson found 64% and 
62% of studies investigating depression and anxiety showed a significant increase in depressive 
or anxiety symptoms in chronic tinnitus sufferers compared to healthy controls, respectively.   
Consequently, a positive association between limbic system dysfunction and chronic tinnitus 
may be present.  This migrates the focus away from a wholly peripheral auditory dysfunction and 
allows the introduction of central factors.   
 Other studies of limbic system involvement in chronic tinnitus examined brain imaging in 
tinnitus patients and healthy controls.  Leaver et al. (2012) discovered reduced grey matter 
volume in the ventromedial prefrontal cortex (vmPFC), which has also been linked to depression 
and anxiety.  They suggest this causes a failure to suppress aberrant activity in the auditory 
system.  Additionally, Besteher et al. (2019) report grey matter alterations in tinnitus patients are 
highly influenced by comorbid psychiatric disorders.  They implicate the parahippocampal 
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cortex in memory mechanisms related to phantom percept persistence.  A 2011 study by Leaver 
et al. also found robust differences between chronic tinnitus patients and healthy controls in 
limbic areas.  Specifically, they point to reduced grey matter volume in the vmPFC and 
hyperactivity in the nucleus accumbens (NAc).  They suggest chronic tinnitus is caused by a 
compromised limbic corticostriatal circuit.  This lends itself to a “disordered evaluation of the 
tinnitus sensation’s perceptual relevance and an increased gain control of the percept” (p. 37).  In 
other words, the dysfunctional system has difficulty determining which sensations are important 
and how they are experienced, making the sound perhaps perceptually louder than if measured in 
decibels. 
 Jastreboff and Jastreboff (2001) indicate TRT avoids further excitation of the limbic 
system to prevent changing the tinnitus signal.  The aim is not to mask the signal, but rather to 
allow the patient to habituate.  They further suggest a sound therapy that enhances the activation 
of the limbic system will enhance the tinnitus annoyance.  TRT combines interactive teaching 
and counseling sessions with sound use that is significantly above the threshold of tinnitus 
perception.  In the case of introducing a nutraceutical formulation, the percept, in theory, will 
gradually decrease as the patient follows the proper dosing schedule.  TRT will continue to use 
sound that limits activation of the limbic system, but the threshold above tinnitus perception will, 
again in theory, decrease as the peripheral and central auditory systems improve. 
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CONCLUSION 
Initially this project sought to investigate patient records from the International Hearing 
Centre in Lagos, Nigeria after learning patients reported subjective improvement in bothersome 
tinnitus.  Incomplete charting transformed this research into a review of clinical practice 
guidelines for diagnostic evaluation and suggested timelines for assessing subjective validation 
measures of change to the tinnitus, i.e. the Tinnitus Handicap Inventory.  The goal of this project 
is to implement an evidence-based clinical protocol at the IHC to standardize patient care in 
order to evaluate and statistically analyze the efficacy of the NH formulation on subjective 
tinnitus sufferers in the future.  Future research can use this project as a template to assess 
changes to tinnitus percept in patients taking the NH formulation.   
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Appendix 1 
Inclusion/Exclusion Checklist  
For use by the clinician 
 
Characteristics Responses Necessary Response for 
Inclusion 
18 years of age or older YES/NO YES 
Chronic tinnitus for 6 months or more YES/NO YES 
Pulsatile or clicking tinnitus? YES/NO NO 
Taken NH for 3 months or more? YES/NO YES 
Current or previous use of other tinnitus 
treatment? 
YES/NO NO 
Tinnitus resolved after cerumen removal? YES/NO NO 
Perforated tympanic membrane? YES/NO NO 
Mass observed behind the tympanic 
membrane? 
YES/NO NO 
Type B tympanograms? YES/NO NO 
Conductive hearing loss or active middle ear 
disease? 
YES/NO NO 
Retrocochlear pathology? YES/NO NO 
Meniere’s Disease? YES/NO NO 
Use of ototoxic medications? YES/NO NO 
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Appendix 2 
Case History Form 
  
Age ________________________ 
Gender _____________________ 
Occupation __________________ 
  
  
Medical History (mark “X” to all that apply) 
___Diabetes 
___Hypertension 
___Cancer (if yes, please specify __________________) 
___Chemotherapy 
___Temporomandibular Disorder (TMJ) 
___Ear surgery 
___Heart problems (please specify _________________) 
___Kidney disease 
___Thyroid disorder 
___Autoimmune disease 
___HIV/AIDS 
___Head or neck trauma 
___Depression, anxiety, sleep disorder 
___Other (please specify _________________________) 
  
Please list all medications you are currently taking: 
______________________________________________________________________________ 
______________________________________________________________________________
______________________________________________________________________________ 
 
Any history of recreational or occupational noise exposure? 
______________________________________________________________________________ 
______________________________________________________________________________ 
  
Any history of hearing loss, ear issues, or vestibular/balance disorder? 
______________________________________________________________________________ 
  
Tinnitus History 
1.     What does it sound like? (e.g. buzz, click, ring, hiss, chirp, other) _______________ 
2.     When did it begin? ____________________________________________________ 
3.     How often does it occur? (e.g. intermittent, constant) _________________________ 
4.     What pitch is the tinnitus? (e.g. high, low, mid) _____________________________ 
5.     How loud is the tinnitus? (e.g. louder than conversation, only in quiet, other)______ 
_______________________________________________________________________ 
6.     Do any sounds effectively mask the tinnitus? _______________________________ 
7.     Does anything provoke or exacerbate the tinnitus? ___________________________ 
________________________________________________________________________ 
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8.     Does anything alleviate the tinnitus? ______________________________________ 
9.     Does the tinnitus stop you from performing daily activities? ___________________ 
  
Answer the following questions with yes, sometimes, or no: 
1.     My tinnitus has led me to avoid social situations ____________________________ 
2.     My tinnitus has led me to think about suicide _______________________________ 
3.     My tinnitus contributes to a feeling of general ill health _______________________ 
4.     I have a healthy outlook on tinnitus _______________________________________ 
5.     I have support from my friends and family regarding my tinnitus _______________ 
  
What percentage of your time awake are you consciously aware of your tinnitus? ____________ 
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Appendix 3 
Tinnitus Handicap Inventory (Newman et al., 1996) 
  
1.     Because of your tinnitus, is it difficult for you to concentrate? Yes (4) Sometimes (2) No 
(0) 
2.     Does the loudness of your tinnitus make it difficult for you to hear people? Yes (4) 
Sometimes (2) No (0) 
3.     Does your tinnitus make you angry? Yes (4) Sometimes (2) No (0) 
4.     Does your tinnitus make you feel confused? Yes (4) Sometimes (2) No (0) 
5.     Because of your tinnitus, do you feel desperate? Yes (4) Sometimes (2) No (0) 
6.     Do you complain a great deal about your tinnitus? Yes (4) Sometimes (2) No (0) 
7.     Because of your tinnitus, do you have trouble falling asleep at night? Yes (4) Sometimes 
(2) No (0) 
8.     Do you feel as though you cannot escape your tinnitus? Yes (4) Sometimes (2) No (0) 
9.     Does your tinnitus interfere with your ability to enjoy your social activities (such as 
going out to dinner, to the movies)? Yes (4) Sometimes (2) No (0) 
10.  Because of your tinnitus, do you feel frustrated? Yes (4) Sometimes (2) No (0) 
11.  Because of your tinnitus, do you feel that you have a terrible disease? Yes (4) Sometimes 
(2) No (0) 
12.  Does your tinnitus make it difficult for you to enjoy life? Yes (4) Sometimes (2) No (0) 
13.  Does your tinnitus interfere with your job or household responsibilities? Yes (4) 
Sometimes (2) No (0) 
14.  Because of your tinnitus, do you find that you are often irritable? Yes (4) Sometimes (2) 
No (0) 
15.  Because of your tinnitus, is it difficult for you to read? Yes (4) Sometimes (2) No (0) 
16.  Does your tinnitus make you upset? Yes (4) Sometimes (2) No (0) 
17.  Do you feel that your tinnitus problem has placed stress on your relationships with 
members of your family and friends? Yes (4) Sometimes (2) No (0) 
18.  Do you find it difficult to focus your attention away from your tinnitus and on other 
things? Yes (4) Sometimes (2) No (0) 
19.  Do you feel that you have no control over your tinnitus? Yes (4) Sometimes (2) No (0) 
20.  Because of your tinnitus, do you often feel tired? Yes (4) Sometimes (2) No (0) 
21.  Because of your tinnitus, do you feel depressed? Yes (4) Sometimes (2) No (0) 
22.  Does your tinnitus make you feel anxious? Yes (4) Sometimes (2) No (0) 
23.  Do you feel that you can no longer cope with your tinnitus? Yes (4) Sometimes (2) No 
(0) 
24.  Does your tinnitus get worse when you are under stress? Yes (4) Sometimes (2) No (0) 
25.  Does your tinnitus make you feel insecure? Yes (4) Sometimes (2) No (0) 
  
  
The sum of all responses is your THI Score ________________ 
0-16 points – Slight or no handicap 
18-36 points – Mild handicap 
38-56 points – Moderate handicap 
58-76 points – Severe handicap 
78-100 points – Catastrophic handicap 
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Appendix 4 
Petridou et al (2019) Antioxidant Ingredients 
 
Ingredient Amount Per Serving % Daily Value Difference 
Vitamin A 2600 IU 98% ~ half less than NH 
Vitamin C 150 mg 188% 100mg less 
Vitamin D3 400 IU 200% *Vitamin D in NH 
Vitamin E 150 IU 833% 50IU less 
Thiamin 25 mg 2272% 5x as much 
Riboflavin 25 mg 1786% 5x as much 
Niacin 25 mg 156% Same 
Vitamin B6 10 mg 714% 2x as much 
Folic Acid 200 mcg 100% Same 
Vitamin B12 10 mcg 400% Same 
Biotin 150 mcg 300% About half as much 
Pantothenic Acid 25 mg 417% 2x as much 
Calcium 62 mg 8% Same 
Iron 14mg 100% Not found in NH 
Magnesium 50 mg 13% About half as much 
Zinc 15 mg 150% Same 
Selenium 100 mcg 200% Same 
Chromium 200 mcg 500% Almost 4x as much 
Molybdenum 500 mcg 1000% Not found in NH 
Iodine 150 mcg 100% Not found in NH 
Choline, Inositol, PABA 25mg each Not specified Not found in NH 
Grapeseed extract 500 mg Not specified Not found in NH 
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